-D F Hayes Researcher Activity Profile

Research Author Detailed Information 

D F Hayes Publication Rate By Year

D F Hayes has published 1 paper(s) in 1988, 1 paper(s) in 1996, 1 paper(s) in 1999, 1 paper(s) in 2001, 2 paper(s) in 2006, 16 paper(s) in 2007, 2 paper(s) in 2008, for a total of 24 research publications in total.

D F Df Hayes Author Information

LAST NAME: hayes

FIRST NAME: D F

INITIALS: df

AFFILIATION:

Papers

D F Hayes's Publication Record

1. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Year Published: 2001
The Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20007, USA.
2. Point-of-care biosensor systems for cancer diagnostics/prognostics. Year Published: 2006
Louisiana State University, Baton Rouge, LA 70803, United States. chsope@lsu.edu
3. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Year Published: 2006
Department of Internal Medicine, Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109, USA. hayesdf@umich.edu
4. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Year Published: 2007
Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA. lyndsay.harris@yale.edu
5. The pharmacogenetics research network: from SNP discovery to clinical drug response. Year Published: 2007
Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, California, USA. kathy.giacomini@ucsf.edu
6. HER2 and response to paclitaxel in node-positive breast cancer. Year Published: 2007
Breast Oncology Program,University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA. hayesdf@umich.edu
7. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Year Published: 2007
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109-0848, USA. rlayman@umich.edu
8. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Year Published: 2007
Department of Surgery, The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
9. HER2 and response to paclitaxel in node-positive breast cancer. Year Published: 2007
Breast Oncology Program,University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA. hayesdf@umich.edu
10. Angiogenesis as targeted breast cancer therapy. Year Published: 2007
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 CCGC, Ann Arbor, MI 48109, USA.
11. Simulation of resuspended sediments resulting from dredging operations by a numerical flocculent transport model. Year Published: 2007
Department of Environmental Health and Safety, University of Nevada, Reno, NV 89557, United States.
12. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Year Published: 2007
Yale Cancer Center, Yale University, New Haven, CT, USA.
13. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Year Published: 2007
Yale Cancer Center, Yale University, New Haven, CT, USA.
14. Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. Year Published: 2007
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109-5843, USA. norahh@med.umich.edu
15. HER2 and response to paclitaxel in node-positive breast cancer. Year Published: 2007
Breast Oncology Program,University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA. hayesdf@umich.edu
16. Angiogenesis as targeted breast cancer therapy. Year Published: 2007
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 CCGC, Ann Arbor, MI 48109, USA. hayesdf@umich.edu
17. Serum (circulating) tumor markers for breast cancer. Year Published: 1996
Breast Evaluation Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
18. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Year Published: 2007
Department of Surgery, The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
19. Simulation of resuspended sediments resulting from dredging operations by a numerical flocculent transport model. Year Published: 2007
Department of Environmental Health and Safety, University of Nevada, Reno, NV 89557, USA. cje@unr.edu
20. The prognostic implications of circulating tumor cells in patients with breast cancer. Year Published: 2008
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
21. Determination of clinical utility of tumor markers: a tumor marker utility grading system. Year Published: 1999
Breast Cancer Center Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
22. International Web-based consultation on priorities for translational breast cancer research. Year Published: 2008
Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK,. mitch.dowsett@icr.ac.uk.
23. Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. Year Published: 1988
Laboratory of Clinical Pharmacology, Dana Farber Cancer Institute, Boston, Massachusetts.
24. Angiogenesis as targeted breast cancer therapy. Year Published: 2007
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 CCGC, Ann Arbor, MI 48109, USA. hayesdf@umich.edu